CSS
CRNX icon

Cubist Systematic Strategies’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cubist Systematic Strategies’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13
Closed -$374 – 3088
2025
Q2 		$374 Buy
+13
New +$401 ﹤0.01% 2887
2023
Q3 		– Sell
-47,192
Closed -$850K – 3433
2023
Q2 		$850K Buy
47,192
+46,092
+4,190% +$919K 0.01% 2062
2023
Q1 		$17.7K Buy
+1,100
New +$20.4K ﹤0.01% 3677
2022
Q4 		– Sell
-1,925
Closed -$38K – 4296
2022
Q3 		$38K Sell
1,925
-6,553
-77% -$134K ﹤0.01% 4160
2022
Q2 		$158K Buy
8,478
+3,503
+70% +$69.9K ﹤0.01% 3791
2022
Q1 		$109K Buy
4,975
+3,348
+206% +$67.8K ﹤0.01% 3214
2021
Q4 		$46K Sell
1,627
-19,311
-92% -$476K ﹤0.01% 3318
2021
Q3 		$441K Buy
20,938
+8,657
+70% +$181K 0.01% 2120
2021
Q2 		$231K Buy
12,281
+12,264
+72,141% +$216K ﹤0.01% 2467
2021
Q1 		$0 Sell
17
-1,151
-99% -$17.8K ﹤0.01% 2850
2020
Q4 		$16K Buy
+1,168
New +$16.3K ﹤0.01% 2508
2020
Q3 		– Sell
-1,483
Closed -$26K – 2506
2020
Q2 		$26K Buy
+1,483
New +$25.3K ﹤0.01% 2304
2020
Q1 		– Sell
-4,700
Closed -$118K – 2208
2019
Q4 		$118K Buy
4,700
+2,922
+164% +$55.6K ﹤0.01% 2155
2019
Q3 		$27K Buy
+1,778
New +$34.6K ﹤0.01% 2102

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cubist Systematic Strategies's CRNX Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 13 shares — an estimated $374 sold.

Cubist Systematic Strategies first reported a position in CRNX in Q3 2019 and held it in 14 quarters. The position peaked at $850K in Q2 2023. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 13 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $374.
  • Cubist Systematic Strategies first reported a position in Crinetics Pharmaceuticals in Q3 2019 and held it in 14 quarters.
  • Cubist Systematic Strategies's Crinetics Pharmaceuticals position peaked at $850K in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.